Public Market Listing
Live quotes, historical charts, and market capitalization for Luye Pharma Group are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(12 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | Alkylating DrugSmall molecule | Small Cell Lung Cancer | |
| Approved | Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | Schizophrenia | |
| Approved | Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | SchizophreniaBipolar Disorder | |
| Approved | Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | SchizophreniaBipolar Disorder | |
| Phase 3 | Serotonin/norepinephrine/dopamine transporterSmall molecule | Major Depressive Disorder | |
Evogliptin(Suganon) | Phase 3 | DPP-4Small molecule | Type 2 Diabetes |
LY01008No recent activity | Phase 3 | VEGF-AMonoclonal antibody | Non-Small Cell Lung CancerColorectal Cancer |
| Phase 3 | Dopamine receptorsSmall molecule | Parkinson's Disease | |
| Phase 2 | Serotonin 5-HT2A receptor (antagonist / inverse agonist) · 5-HT2A/5-HT2C · 5-HT2A/2C receptorSmall molecule | Alzheimer's DiseaseParkinson's DiseaseSchizophrenia | |
| Phase 2 | 5-HT2C/TAAR1 receptorSmall molecule | Alzheimer's DiseaseSchizophrenia | |
| Phase 1 | Norepinephrine/dopamine transporter + GABA-A receptorSmall molecule | Major Depressive Disorder | |
Rotigotine (LY03009)No recent activity | Phase 1 | dopamineSmall molecule | Parkinson's Disease |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
December 2027 (2)
What to watch
2028 (1)
January 2028 (1)
What to watch
Regulatory and conference events
(7)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (2)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-H1 | $439M | — | — | — | report ↗ |
Luye Pharma reported interim 2025-H1 revenue of RMB3.181 billion, up 3.46% YoY, with the structured financial row listing revenue of $438.93M. Profit attributable to owners of the parent company was RMB313 million, down 19.33% YoY, with EPS of 8.32 cents. R&D spend and cash position were not disclosed for the period, though prior-year R&D spend was $38.92M.
The group noted its major products hold competitive positions in oncology, CNS, cardiovascular, and metabolism in China, where IQVIA ranked these as the first, second, fourth, and fifth largest pharmaceutical markets. By treatment area, oncology revenue rose 13.5% to RMB1.295 billion, CNS revenue grew 5.4% to RMB868 million, cardiovascular revenue declined 9.2% to RMB693 million, and metabolism revenue fell 7.9% to RMB180 million. The group also detailed its China and international product portfolios, with international offerings focused on CNS, and stated its 18 major products are expected to see steady or maintained market share.
View 1 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-H1 | — | $39M | — | — | report ↗ |
Annual history (3 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $878M | — | — | — | report ↗ |